Cardiology Dissertation Topics: Researchable Ideas With Real Data and Ethics Routes

Questions to Settle Before You Choose Your Cardiology Dissertation Topic
Cardiology dissertation topics range from a desk-based review of heart failure drugs to a data project built on an NHS audit, and the right choice depends on what you can actually access. Settle these questions about your own project first:
- Can I answer my question with published audit reports, open data or a systematic review, or do I really need patient-level records?
- If my project involves NHS patients or records, does my level of study even allow NHS ethics review?
- Am I studying a drug, a test, a risk score, a service or a patient group, and which outcome will I measure?
- Which guideline will define my terms, such as the heart failure categories, the hypertension pathway or the atrial fibrillation approach?
- Can I finish within my timeline without a long follow-up period?
- Does my question belong in cardiology, or is it really a nursing, public health or health economics project?
This resource treats cardiology as a medical and health-science subject: coronary disease, heart failure, rhythm disorders, valve disease, hypertension and prevention, imaging, congenital heart disease and cardio-oncology. Questions about nursing care on the cardiac ward fit better with the cardiac nursing dissertation topics, and wider clinical ideas sit under medicine dissertation topics.
Position correct as of October 2026. Several topics below rest on guidance that was recently updated or is being updated, including NICE heart failure guidance (updated 2025), NICE heart valve guidance (an update on TAVI is in development) and the ESC guidelines released in 2025. Each is flagged where it appears, so check NICE and the ESC guidelines page for the current status before you lock a protocol.
Heart Failure Dissertation Topics: NICE NG106, SGLT2 Inhibitors and the National Audit
NICE updated its chronic heart failure guideline NG106 in 2025, and heart failure is one of six domains in NICOR’s National Cardiac Audit Programme, so this area offers both current guidance and a national data source. Each topic names what it rests on, and the explanation says what level suits it. Where a topic is set in England, the same method usually transfers to your own country, so adjust the setting rather than treating it as a new topic.
1. To what extent have NICE technology appraisals TA679 and TA773 shifted prescribing of dapagliflozin and empagliflozin in England, using the NHSBSA English Prescribing Dataset with SNOMED codes?
TA679 covers dapagliflozin and TA773 covers empagliflozin for heart failure with reduced ejection fraction. The NHSBSA dataset publishes monthly dispensed items, so an interrupted time series around each publication date fits a Master’s project. It cannot show why a drug was prescribed, so state that limit early. Some local formularies now name generic dapagliflozin as first line for new patients, which is worth checking before you interpret any switch. The pharmacology dissertation topics page may help if the drug side interests you more.
2. How far has NICE’s instruction in TA929 to choose the least expensive suitable option between empagliflozin and dapagliflozin held in practice for heart failure with preserved or mildly reduced ejection fraction?
TA929 recommends empagliflozin and says to use the cheaper option when clinicians consider both suitable, because no trial compares them directly. A cost-comparison study using prescribing data and published list prices suits a health economics student. List prices change, so state the month you used.
3. Whether referral of people with heart failure to cardiac rehabilitation falls away between inpatient referral and programme completion, as NICE quality standard QS9 expects it to be measured, using National Heart Failure Audit and National Audit of Cardiac Rehabilitation reports.
QS9 names both audits as data sources for its cardiac rehabilitation statement, so the measurement framework already exists. Published reports are enough at undergraduate level. Linking patient-level records across the two audits is a PhD-scale access task.
4. How accurate are natriuretic peptide-first pathways at ruling heart failure in or out in people with suspected heart failure, as set out in NICE NG106?
This is a diagnostic test accuracy review: search for studies reporting sensitivity and specificity at the thresholds NG106 uses, assess bias with QUADAS-2 and pool with a bivariate model only if studies are similar enough. Do not mix emergency department and primary care studies without checking prevalence.
5. What do heart failure nurses and cardiologists weigh when deciding the order and pace of starting beta blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors and sacubitril valsartan?
Local formulary guidance describes these as foundational therapies for reduced ejection fraction, yet sequencing is left to clinical judgement. Interviews with NHS staff recruited for their professional role do not normally need NHS research ethics committee review, but you still need university ethics and NHS site permission, so allow time. Reflexive thematic analysis suits the data.
6. How consistently do hospital echocardiography reports label left ventricular ejection fraction in the mildly reduced range, and does the label change the treatment recommended?
NICE’s appraisals group preserved and mildly reduced ejection fraction together, while some other guidance treats the mildly reduced band as its own category, so reports can differ. A service evaluation of anonymised reports at one trust is realistic. Confirm with the trust whether it counts as audit or research, using the HRA decision tool, before you collect anything.
7. How do heart failure clinics screen for depression and anxiety compared with the 2025 ESC clinical consensus statement on mental health and cardiovascular disease?
The statement is the ESC’s first of its kind on this subject. A short survey of clinics, or a content analysis of the screening tools named in published pathways, keeps the project feasible at Master’s level. Avoid claims about what clinics do until your own data say so.
8. When do specialist heart failure teams refer people to palliative care, following the 2025 update to NG106 that asks multidisciplinary teams to refer directly to services such as palliative care?
Interviews with team members, or an analysis of local referral pathway documents, avoid the need to approach patients. A vignette approach lets you compare how different professionals respond to the same case.
9. How do local formularies set renal function review thresholds for SGLT2 inhibitors in heart failure compared with type 2 diabetes, and what does the difference mean for prescribing safety?
One regional formulary document gives different review thresholds for the two indications, and dapagliflozin also has a NICE appraisal for chronic kidney disease (TA1075). Comparing documents from several integrated care boards needs no patient data, so it suits undergraduates. Link the findings to the nephrology dissertation topics if kidney function becomes your main angle.
10. Which outcomes matter most to people living with heart failure, and does the Minnesota Living with Heart Failure Questionnaire capture them?
The questionnaire is scored from 0 to 105 and is used in exercise rehabilitation trials. A review of its measurement properties, followed by a small qualitative check against patient-reported priorities in published studies, makes a clear Master’s project.
11. How do older people with heart failure experience exercise-based cardiac rehabilitation delivered at home, in the community or in hospital, as NG106 allows?
NICE recommends a personalised exercise-based programme that can be delivered in any of these settings. A qualitative evidence synthesis keeps you away from NHS patient recruitment, which matters at undergraduate level.
12. How representative are the trial populations behind TA929 of the people NICE expected to be eligible for empagliflozin in heart failure with preserved or mildly reduced ejection fraction?
Compare baseline tables from the pivotal trial with published UK heart failure registry or audit descriptions on age, sex, frailty and kidney function. The result is a clear argument about generalisability. Avoid claiming the trial was flawed; describe what is and is not covered.
13. Does titrating treatment to natriuretic peptide levels improve outcomes compared with titrating to symptoms alone in heart failure with reduced ejection fraction?
Update an existing meta-analysis of randomised trials and examine heterogeneity by age and ejection fraction. Pre-register the protocol where your university supports it, and report the certainty of evidence with GRADE.
14. How effective is intravenous iron at improving exercise capacity and reducing heart failure hospitalisation in people with iron deficiency, and does the effect differ between ferric carboxymaltose and ferric derisomaltose?
A focused systematic review with a clear comparison between named preparations. The main pitfall is pooling trials that define iron deficiency differently, so tabulate each definition before you pool.
15. Why do some people stop sacubitril valsartan after starting it, and what could services do to keep them on treatment?
A mixed-methods project works well: count discontinuation in a local prescribing audit, then interview a small group of prescribers or pharmacists. Keep to a service evaluation unless your university and the trust agree it is research.
Coronary Artery Disease and Acute Coronary Syndrome Research Topics
The Myocardial Ischaemia National Audit Project (MINAP) records care for people admitted with type 1 myocardial infarction and sits inside NICOR’s programme, alongside the percutaneous coronary intervention audit. Patient-level extracts require an application to NICOR, whereas the published annual reports are open and are the realistic route for most students.
16. Do call-to-balloon and door-to-balloon times in MINAP differ by ethnic group after adjusting for age, sex and mode of presentation?
MINAP records process measures for hospitals and ambulance services. NCAP reports have shown that Asian and Black patients are younger at the time of a heart attack, so age needs careful handling. Check the data dictionary for how complete the ethnicity field is before you commit.
17. How does age at first heart attack vary by ethnic group in NCAP reports, and what does earlier onset mean for the 25 to 84 age range in which NICE recommends QRISK3?
The published NCAP reports give group-level figures that an undergraduate can describe and discuss without patient data. At Master’s level, add a modelling step that shows how many younger people fall outside the tool’s range.
18. How closely do UK hospitals meet the British Cardiovascular Intervention Society standard for radial artery access in percutaneous coronary intervention, as reported in the NICOR audit?
The 2019 NCAP report described radial access as the preferred route and noted that all but ten hospitals met or exceeded the standard. A trend analysis across later reports shows whether the remaining gap has closed. Use the most recent report you can find.
19. How do the 2025 ACC/AHA acute coronary syndromes guideline and NICE guideline NG185 differ in their antiplatelet recommendations for NSTEMI, and what evidence explains the differences?
The American guideline published in February 2025 replaced the separate STEMI and NSTE-ACS guidelines with one document covering unstable angina, NSTEMI and STEMI. A structured comparison table, then a discussion of the trials behind each recommendation, makes a rigorous desk-based project.
20. Which predicts in-hospital death or reinfarction better in NSTEMI at a single centre, the GRACE score or the TIMI score?
Compare the two scores with C-statistics in a retrospective cohort. Both need complete variables, so check missing data first. Allow time for NHS research and development approval, or use an audit framing where your trust permits it.
21. What is the prognosis of myocardial infarction with non-obstructive coronary arteries compared with obstructive disease?
A systematic review and meta-analysis of cohort studies, with attention to how each study defines the condition. Different definitions explain much of the variation, so record them in a table.
22. What is known about recurrence, antithrombotic strategy and long-term outcomes after spontaneous coronary artery dissection?
A scoping or systematic review suits undergraduate and Master’s levels. Registry-based studies dominate, so appraise selection bias carefully.
23. Which people with left main coronary disease do better with bypass surgery or stenting, once the SYNTAX score is taken into account?
Pool randomised trial results and compare subgroups by anatomical complexity. State clearly whether you are analysing trial-level or patient-level data, because the second needs access you may not have.
24. What are the long-term outcomes of Takotsubo syndrome compared with acute coronary syndrome?
A systematic review that compares mortality, recurrence and heart failure. Takotsubo is often described as benign, so test that assumption against the evidence rather than repeating it.
25. How accurate are single-sample high-sensitivity troponin rule-out pathways in people with chronic kidney disease presenting with chest pain?
A diagnostic test accuracy review focused on a subgroup that is often excluded from headline trials. Look for studies that report results by kidney function, and be explicit when none do.
26. Are LDL-cholesterol goals met within a year of an acute coronary syndrome, and what predicts the people who miss them?
A retrospective single-centre audit using NICE statin intensity recommendations as the standard. Record what you count as a goal in advance, so that the definition does not drift when you see the data.
Atrial Fibrillation and Arrhythmia Dissertation Topics
Atrial fibrillation sits at the centre of NICE guideline NG196, which advises manual pulse palpation when atrial fibrillation is suspected. Screening policy, anticoagulation and devices all give researchable questions with published evidence, and the CVDPREVENT audit adds a primary care data source.
27. How do detection yields differ between pulse-palpation-led opportunistic screening in the D2AF trial and single-lead ECG screening in VITAL-AF, and what do they imply for NG196’s pulse palpation recommendation?
D2AF was a Dutch cluster trial in people aged 65 and over, and VITAL-AF a United States trial using a handheld single-lead ECG during routine visits. A narrative or systematic comparison of design, population and yield is enough for an undergraduate project.
28. Why do the ESC and NICE differ on atrial fibrillation screening, with the ESC recommending opportunistic screening from 65 and systematic screening offered from 75 while NICE focuses on people with symptoms?
A policy analysis comparing evidence thresholds, cost-effectiveness reasoning and screening criteria. Dates matter here, so cite the version of each document and note that recommendations can change.
29. How much do practices and primary care networks vary on the atrial fibrillation treatment indicators in the CVDPREVENT open data tool?
CVDPREVENT extracts routinely held GP data on atrial fibrillation, hypertension, high cholesterol, diabetes, non-diabetic hyperglycaemia and chronic kidney disease. The open data tool needs no patient access, which makes this realistic for undergraduates. Add deprivation data at Master’s level to explain the variation.
30. How many new atrial fibrillation diagnoses does an emergency department make, and what share of those patients go on to be anticoagulated?
A NICE shared learning example reviewed emergency department ECGs and found a small but meaningful share of new diagnoses. Replicating the design at another site is feasible as a service evaluation. Check with the trust whether it counts as audit or research.
31. Is anticoagulation prescribed in line with CHA2DS2-VASc scores in a single-centre atrial fibrillation clinic?
A retrospective audit that compares prescribing with the score recorded at diagnosis. Decide in advance how to handle people with contraindications, because they change the interpretation of any gap.
32. How much do hospitals vary in implantable cardioverter-defibrillator and pacemaker implantation rates reported by the National Audit of Cardiac Rhythm Management?
The audit covers adults with implanted devices and those receiving interventional rhythm procedures. Published reports let you describe regional variation; explaining it needs population need data such as age structure and disease prevalence.
33. Do subcutaneous implantable cardioverter-defibrillators match transvenous devices for appropriate shocks and device complications?
A systematic review with meta-analysis. Observational studies carry selection bias because the two devices go to different people, so separate randomised and observational evidence.
34. Does catheter ablation improve quality of life more than antiarrhythmic drugs in recurrent atrial fibrillation, as measured by the AFEQT questionnaire?
Focus on patient-reported outcomes rather than rhythm recurrence alone. The main design question is whether the studies used comparable follow-up times.
35. How accurately do consumer smartwatches and single-lead ECG devices detect atrial fibrillation compared with a 12-lead ECG, and how do false positives affect clinic workload?
A diagnostic test accuracy review that includes a short model of follow-up burden. Do not rely on manufacturer-funded studies alone; report funding in your appraisal.
36. How often are hospital inpatients on QT-prolonging drugs monitored with an ECG, and does monitoring follow local policy?
A single-site audit with a clear standard taken from the trust’s own medicines policy. The project is small, achievable and relevant to patient safety.
37. How long does it take from first recorded atrial fibrillation to first anticoagulant prescription in CPRD Aurum, and how does it vary by age, sex and deprivation?
CPRD holds linked primary care, hospital and death records, and the protocol goes through independent scientific review. Student access normally runs through a supervisor’s university licence, so ask early. This is a PhD or advanced Master’s route.
38. Is left atrial appendage occlusion as safe and effective as direct oral anticoagulants in people with atrial fibrillation who can take either?
A comparative review that separates randomised from registry evidence. Pay attention to which people were excluded, since those who cannot take anticoagulants form the main clinical use.
Hypertension and Cardiovascular Risk Dissertation Topics
Hypertension questions sit in NICE guideline NG136, partly updated in March 2022 for people with established cardiovascular disease, and risk questions sit in NG238, which recommends QRISK3 for people aged 25 to 84 without cardiovascular disease.
39. Are blood pressure targets for adults with established cardiovascular disease, set in the March 2022 partial update of NICE NG136, being met in primary care?
NG136 originally excluded people with established cardiovascular disease, and the update added targets and drug treatment recommendations. CVDPREVENT hypertension indicators give a practice-level starting point. Remember that audit data show control, not reasons for it.
40. How do the 2025 AHA/ACC hypertension guideline and NICE NG136 differ on treatment thresholds and on renal denervation for selected people with resistant hypertension?
A document analysis with a transparent comparison framework. Treat the American guideline as a separate system with different populations and cost assumptions, and say so in your discussion.
41. How much does lipid-lowering treatment for people with a QRISK score of 10% or more vary between practices and primary care networks in CVDPREVENT, and which area characteristics explain it?
NICE has cited the audit’s finding that fewer than half of people with a score of 10% or more were on lipid-lowering therapy at the time of the second annual report. Mapping practice characteristics against treatment is a clear Master’s data task.
42. Do SCORE2 and QRISK3 classify the same people as high risk when applied to the same UK Biobank participants?
The 2025 ESC focused update on dyslipidaemia recommends SCORE2 and SCORE2-OP, while NICE recommends QRISK3. UK Biobank may hold the variables needed, but check each one before you commit. Volunteers are healthier than the general population, so discuss how that affects absolute risk estimates. A reduced-fee tier exists for student data-only applications; check the current terms.
43. How does QRISK3’s inclusion of conditions such as severe mental illness, migraine and rheumatoid arthritis change who crosses the 10% threshold compared with QRISK2?
A comparison in a primary care sample, or a careful review of published validation studies if you cannot access records. Report reclassification as net numbers and as percentages of each group.
44. How do GPs use QRISK3-lifetime when discussing risk with people whose 10-year score is below 10%, as NG238 suggests they consider?
NG238 suggests considering a lifetime tool to motivate lifestyle change, especially for people under 40 with risk factors. Interviews with GPs, recruited for their professional role, are a feasible qualitative design. Compare what they say with the recommendation itself.
45. How accurate is home blood pressure monitoring compared with ambulatory monitoring for confirming a diagnosis of hypertension, and does accuracy depend on the measurement schedule?
A diagnostic accuracy review of studies that use ambulatory monitoring as the reference standard. Record the number of readings and days used in each study, because protocols vary.
46. How do hypertension awareness, treatment and control compare between adults in NHANES and the Health Survey for England?
Both surveys publish public-use data, which suits an international student working without NHS access. Harmonise definitions of hypertension and treatment before comparing anything. See the CDC’s NHANES data page for file structure.
47. How often is primary aldosteronism tested for in people with resistant hypertension in English primary care records, and what predicts testing?
Look for a coded test or referral in linked records. This is a PhD-level project because case definitions need clinical input. A simpler undergraduate version is a review of guideline recommendations on when to test.
48. Do polygenic risk scores improve coronary artery disease prediction beyond QRISK3 in UK Biobank?
A strong Master’s or PhD project that needs genotype data and computing skills. Compare discrimination and reclassification, and report how ancestry affects performance. The genetics dissertation topics page covers the genetics side of this question.
49. How many adults with probable familial hypercholesterolaemia remain undiagnosed in primary care records, and which record-based flags would find them?
QRISK3 is not used for people at high risk because of familial hypercholesterolaemia, so missed diagnosis also means missed treatment. A prevalence-style analysis with a case-finding algorithm suits a Master’s data project.
50. How well could routine GP record data prioritise adults for a full formal QRISK3 assessment, the approach in NICE’s updated cardiovascular risk and lipid modification quality standard?
The quality standard update was in draft form in 2025, so check whether it has been finalised before you cite it. The design is a prediction problem: build a simple record-based flag and test how many high-risk people it catches.
51. Do salt substitutes lower blood pressure and cardiovascular events enough to justify population-level advice?
A systematic review that separates blood pressure trials from event trials and discusses safety in people with kidney disease. International relevance is strong because dietary patterns differ widely.
Valvular Heart Disease and Structural Cardiology Research Topics
NICE guideline NG208 covers heart valve disease in adults, and NICE decided in October 2025 to update its recommendations on transcatheter aortic valve implantation. The scope for that update is dated April 2026, so treat the guideline as in development when you write.
52. Is TAVI cost-effective compared with surgical aortic valve replacement for adults at low or intermediate surgical risk, the question NICE has scoped for its NG208 update?
A Markov model built from published trial data suits a Master’s health economics project. The guideline update is pending, so frame your work around the enduring evidence question and describe NICE’s process as ongoing. See health economics dissertation topics for method ideas.
53. How has the surgical risk profile of people receiving TAVI in the UK changed over time, according to NICOR’s published TAVI registry reports?
The registry’s interactive reports are public, so an undergraduate can describe trends without patient data. State clearly which risk score the registry uses for each year.
54. How do heart teams decide between TAVI and surgery for older adults, given that the 2025 ESC/EACTS guideline strengthens the role of multidisciplinary Heart Teams and Heart Valve Centres?
An observational or interview study of decision-making. Observing meetings needs NHS site permission and careful handling of patient information, so a vignette or interview design is simpler.
55. What changed between the 2021 and 2025 ESC/EACTS valvular heart disease guidelines on sex-specific considerations, and what evidence supports each change?
The 2025 guideline extended and regrouped sex-specific considerations into a dedicated section. A narrative review that traces each recommendation back to its evidence is a good test of critical appraisal at Master’s level.
56. How well does the diagnostic algorithm in the 2023 ESC endocarditis guidelines classify patients compared with earlier criteria in published validation studies?
A diagnostic accuracy review that treats surgical or pathological findings as the reference standard where available. Report how each study defined definite and possible cases.
57. How has the burden of rheumatic heart disease changed across Global Burden of Disease regions between 1990 and 2021, and which regions are falling behind?
The GBD Results Tool provides free estimates for non-commercial use, so this is accessible to international students. Use joinpoint or annual percentage change methods and acknowledge that estimates are modelled, not observed, in many settings.
58. Are direct oral anticoagulants as safe and effective as warfarin in the early months after bioprosthetic valve implantation?
A systematic review that separates surgical from transcatheter valves and aortic from mitral positions. Pooling across these groups hides real differences.
59. How closely do primary care referrals for echocardiography follow NG208’s referral guidance for suspected heart valve disease, and where do delays arise?
An audit of referral-to-echocardiography times at one hospital or network. The standard is clear and the data are routine, which makes it workable as a service evaluation.
60. What do surveillance intervals and aortopathy follow-up look like for adults with bicuspid aortic valve in published guidance?
A comparative review of international guideline recommendations. The value lies in identifying where guidelines disagree and why.
Cardiac Rehabilitation and Secondary Prevention Topics
The National Audit of Cardiac Rehabilitation (NACR) collects data on access, equity and quality of programmes in England, Wales and Northern Ireland, and the British Heart Foundation summarises its key themes. These topics suit students who prefer service-level questions to clinical trials.
61. Why do women attend cardiac rehabilitation less often than men, and which programme features narrow the gap?
The British Heart Foundation reports that women are less likely to attend. A systematic review with qualitative synthesis could compare barriers and test whether any intervention features recur in programmes with smaller gaps.
62. Is there a relationship between the number of patients a cardiac rehabilitation programme treats and its outcomes, as an NACR-based study set out to test in 2015, and does it hold in recent data?
The earlier study used audit data from 2012 to 2013, so a replication is clear and well scoped. Confirm what data the audit team can share before committing.
63. Do cardiac rehabilitation services certified through the BACPR national certification programme achieve better outcomes in NACR data than uncertified services?
The programme measures services against quality standards, and NACR publishes outcome reporting. Frame the question as an association and discuss selection effects, because well-run services may be more likely to seek certification.
64. Is digitally delivered cardiac rehabilitation as effective as centre-based programmes for exercise capacity and quality of life?
A systematic review that separates fully remote, hybrid and telephone-supported programmes. A 2021 BMJ paper on virtual and in-person cardiac rehabilitation is a useful starting point for the reference list.
65. Has any trial since the 2019 Cochrane review of exercise-based cardiac rehabilitation for heart failure shown an effect on hospital admission or death, particularly in preserved ejection fraction?
The NIHR summary of earlier evidence reported small gains in quality of life and fitness without a clear effect on death or admission. An update review that tests whether newer trials change that picture is a clean, answerable question.
66. How do anxiety and depression scores change across a cardiac rehabilitation programme in NACR reports, and which patient groups improve least?
NACR reports have described falls in clinical depression after programmes. Subgroup analysis by age, sex and diagnosis shows where support may need to differ.
67. Is a hybrid cardiac rehabilitation programme feasible for people aged over 75, and what would a feasibility trial need to measure?
A protocol-only project is valid at Master’s level if your university allows it. Specify recruitment, retention, adherence and safety outcomes, and justify the sample size for feasibility rather than for effectiveness.
68. Do peer-led support groups improve adherence to cardiac rehabilitation and secondary prevention medicines?
A review of randomised and quasi-experimental studies. Ask what adherence was measured with, since self-report and dispensing records can disagree.
AI, Imaging and Digital Cardiology Dissertation Topics
Artificial intelligence is moving quickly in cardiology, but NHS adoption is cautious. NICE published its early-use assessment on AI-assisted echocardiography for heart failure in May 2026, so evidence questions rather than technology claims make the strongest dissertations.
69. What real-world evidence would NICE need to move AI-assisted echocardiography software such as EchoConfidence, EchoGo Heart Failure, Ligence Heart and Us2.ai from early-use to routine adoption for heart failure?
NICE’s HealthTech guidance (HTG779) found limited evidence of time savings and no robust UK real-world evidence, and placed the tools in an early-use category for research and evaluation settings. A Master’s or PhD project can design an evaluation protocol or time-and-motion study. Guidance can change, so cite the version date. The artificial intelligence dissertation topics page offers technical angles.
70. How do British Society of Echocardiography members expect AI to change the work of accredited echocardiographers, and which skills need strengthening?
The society has said AI is likely to augment rather than replace practice and that validating outputs becomes more important. A survey of accredited staff is a feasible design with staff participants, but you still need university ethics.
71. How does the positive predictive value of AI-enabled ECG screening for left ventricular systolic dysfunction change with disease prevalence, and when does a high negative predictive value justify using it to prioritise echocardiography?
Published reviews describe high discrimination but prevalence-dependent predictive values, including in emergency patients with breathlessness. A systematic review with a worked example at three prevalence levels makes the idea concrete.
72. Is AI-ECG performance maintained when algorithms trained at one centre are tested at another?
The 2022 systematic review of AI-enabled ECG screening is a good anchor. Extract external validation results separately from internal ones, and look for confounders such as age and sex that the original studies reported.
73. Which cardiovascular research topics have grown since the 175-topic map published in the European Heart Journal in 2019?
Gal and colleagues used natural language processing and topic modelling on 478,000 publications from 2004 to 2013, and found hot topics such as TAVI, imaging and stem cells. A bibliometric update using recent PubMed records suits a computing or data science student. Latent Dirichlet allocation and network mapping are the methods to learn.
74. Do cardiac MRI measures of left ventricular mass or volume in UK Biobank improve prediction of heart failure beyond age and blood pressure?
A cardiac MRI subset exists within the cohort and has been described in published work. Check imaging availability for your outcome of interest and follow-up time. Suits a Master’s or PhD with statistical modelling skills.
75. What does coronary artery calcium scoring add to QRISK3 when deciding on statin treatment for people near the 10% threshold?
A systematic review of reclassification studies. Discuss radiation exposure and cost alongside the statistical gain.
76. How do people over 65 experience wearable or handheld heart rhythm devices when invited to atrial fibrillation screening?
A qualitative study of acceptability and trust, linked to the single-lead ECG approach in VITAL-AF. Recruitment from community groups avoids NHS patient ethics routes, although you still need university approval.
77. Which barriers to remote monitoring of implanted cardiac devices are reported in the literature, and do they differ between the UK and other health systems?
A scoping review following PRISMA-ScR. The comparison across systems gives an international dimension without needing local data.
78. How well are ethnic minority groups represented in public ECG and echocardiography datasets used to train cardiac AI?
A data audit of dataset documentation and published model cards. The result is a concrete description of bias risk rather than a general warning.
79. Which cardiometabolic characteristics measured at baseline predict first hospital admission for heart failure in Our Future Health participants?
Our Future Health holds questionnaire data, clinic measurements, genotype array data and linked NHS England records for more than two million participants, released into a secure environment every three months. Applications go through an access board. This is a PhD-scale project.
80. Can handheld point-of-care ultrasound used by non-cardiologists detect left ventricular dysfunction accurately enough to guide referral?
A diagnostic accuracy review that records the operator’s training level. Accuracy often depends heavily on training, so analyse it as a moderator.
Cardio-Oncology, Pregnancy and Cardiometabolic Heart Disease Topics
These topics sit where cardiology meets another specialty. Several rest on ESC documents published in 2023 or 2025, so confirm which version you are citing.
81. How consistently do UK cancer centres carry out the baseline cardiovascular assessment and surveillance recommended in the 2022 ESC cardio-oncology guidelines before anthracycline or trastuzumab therapy?
A service evaluation or survey of cancer centres. Compare local protocols with the guideline. See the oncology nursing dissertation topics page if the nursing view interests you.
82. Does a relative fall in global longitudinal strain predict later left ventricular dysfunction in people receiving anthracyclines?
A prognostic accuracy review. Compare threshold definitions across studies, because they differ.
83. How does the modified WHO risk classification in the 2025 ESC pregnancy guideline change risk categories for common heart conditions compared with the 2018 version?
The 2025 guideline introduced an updated stratification system, mWHO 2.0. A comparative analysis of published classifications is feasible without any patient data.
84. Do adverse pregnancy outcomes such as pre-eclampsia and gestational diabetes add predictive value to QRISK3 for cardiovascular events in women in the years after pregnancy?
The 2025 ESC guideline highlights links between adverse pregnancy outcomes and future cardiovascular risk. Testing added value needs linked primary care records, which makes it PhD-level work.
85. How do return-to-exercise recommendations for myocarditis in the 2025 ESC guideline compare with those used by athlete screening programmes?
The guideline gives personalised advice on return to work and exercise. A comparative document analysis suits Master’s students in sport and exercise medicine.
86. How do the new LDL-lowering therapies discussed in the 2025 ESC/EAS dyslipidaemia focused update compare with statins in cost-effectiveness according to published NICE appraisals?
A health economics review. Prices and appraisal outcomes change, so date every figure.
87. How well do SGLT2 inhibitor and GLP-1 receptor agonist prescribing patterns in type 2 diabetes line up with the cardiovascular recommendations in the 2023 ESC guidelines on diabetes?
Use the NHSBSA prescribing data to count dispensed items by drug class and region, then discuss the recommendation. Prescribing data do not show indication, so be careful with claims. The endocrinology dissertation topics page may suit you if you prefer the metabolic angle.
88. Why are people with chronic kidney disease less likely than those with established cardiovascular disease to receive lipid-lowering therapy in CVDPREVENT data, and has the gap changed across annual reports?
The first annual report noted lower prescribing in chronic kidney disease. Comparing annual reports shows whether the difference has narrowed, and a policy discussion can follow.
Congenital and Paediatric Cardiology Dissertation Topics
Congenital topics rely heavily on specialist registries and sensitive populations, so desk-based and registry-report designs are usually the most realistic. The National Congenital Heart Disease Audit covers procedures in patients under 16 and adult congenital procedures for defects present from birth. For paediatric nursing angles, see the child health nursing dissertation topics.
89. How have procedure volumes and short-term survival changed for children undergoing congenital heart surgery in the National Congenital Heart Disease Audit’s published reports?
A descriptive trend analysis using public reports. Be careful with year-to-year changes in case mix and coding.
90. What helps young people with congenital heart disease move from paediatric to adult services?
A scoping review of transition interventions. The strongest versions compare outcomes such as appointment attendance and self-management.
91. What are the neurodevelopmental outcomes after cardiac surgery in infancy, and which factors explain the variation?
A systematic review with meta-analysis restricted to studies using standardised developmental assessments. Pool by age at assessment, not across all ages.
92. How do parents experience prenatal diagnosis of congenital heart disease, and what support do they say they needed?
A qualitative evidence synthesis keeps you away from direct contact with families. A primary study needs NHS ethics review and is more suitable for doctoral work.
93. What does the evidence say about the timing of pulmonary valve replacement after tetralogy of Fallot repair?
A narrative or systematic review comparing thresholds for intervention across centres and guidelines.
94. What are the late outcomes of the Fontan circulation in adulthood, and which complications dominate?
A systematic review of cohort studies with long follow-up. Note that survivors form a selected group, so interpret long-term survival carefully.
95. Does ECG screening before sports participation in young athletes detect serious cardiac conditions at an acceptable cost?
A review of screening studies that compares detection, false positives and cost. International screening policies differ, which gives a comparative dimension.
Cardiovascular Public Health, Inequalities and Data Topics
Public health questions often need only open data. The British Heart Foundation publishes a heart and circulatory disease statistics compendium, and global estimates are free through IHME. These topics suit students who want a strong dataset without NHS ethics.
96. How do heart and circulatory disease death rates differ between UK nations and English regions in the 2025 BHF statistics compendium, and which indicators show gaps narrowing or widening?
The compendium was published in June 2025 and covers mortality, morbidity and more. A descriptive comparison with a clear discussion of causes works at undergraduate level.
97. What drives cardiovascular inequalities for women from Pakistani and Bangladeshi communities in the UK, and what would a culturally adapted prevention programme need to include?
A funded PhD project on this theme has been advertised, which shows the area is current. A Master’s version can be a systematic review of interventions or a qualitative study with community partners, subject to university ethics.
98. Is short-term exposure to fine particulate matter associated with hospital admissions for myocardial infarction in English cities?
A time-series study using public monitoring data and admission counts. Control for temperature and season, and explain how you handled missing monitor days.
99. Is the long decline in cardiovascular mortality levelling off in high-income countries, as Global Burden of Disease analysis for the OECD suggested, and does it continue in more recent estimates?
Compare age-standardised rates across countries over time using the GBD tool. Suits international students and reaches beyond the UK.
100. How cost-effective is inviting adults for cardiovascular risk assessment, compared with opportunistic assessment, when risk is calculated with QRISK3?
A model-based evaluation. State your perspective, time horizon and discount rate, and justify any assumption about uptake.
101. How do members of the public feel about sharing genetic and health data in large cohorts such as UK Biobank and Our Future Health?
A survey or focus group study. Recruitment from the general public avoids NHS ethics, but you still need university approval and careful data protection.
102. How do heatwaves and cold spells affect cardiovascular hospital admissions, and which groups are most vulnerable?
A systematic review with attention to age, deprivation and housing. The topic connects cardiology to climate adaptation planning.
103. Do community-based lifestyle programmes lower cardiovascular risk scores in adults with a QRISK3 score of 10% or more?
A systematic review that compares programme intensity and follow-up. Report effect sizes on risk scores and on individual risk factors separately.
Worked Examples With Aims and Objectives
These examples show how a broad idea becomes a project you can finish. Each uses a topic from the lists above, and the research aims and objectives generator can help you draft your own.
Example 1: Master’s, prescribing data
Aim: To measure how monthly dapagliflozin and empagliflozin prescribing in England changed after NICE TA679 and TA773.
- Extract monthly dispensed items for both drugs from the NHSBSA dataset across a defined period.
- Fit an interrupted time series around each publication date and test for level and trend change.
- Compare changes between integrated care boards and discuss what prescribing data cannot show.
Example 2: Undergraduate, systematic review
Aim: To identify why women attend cardiac rehabilitation less often than men and which programme features narrow the gap.
- Search at least three databases using a documented strategy and screening process.
- Appraise included studies with a suitable quality tool and extract barriers by theme.
- Synthesise programme features that recur in studies reporting smaller gaps.
Example 3: Master’s or PhD, UK Biobank
Aim: To compare the classification of cardiovascular risk by SCORE2 and QRISK3 in UK Biobank participants without prior cardiovascular disease.
- Derive both scores from available baseline variables and document any approximations.
- Cross-tabulate classification at each guideline’s threshold and report net reclassification.
- Examine how well each score predicts first cardiovascular events during follow-up.
Example 4: Master’s, qualitative
Aim: To understand how GPs use QRISK3-lifetime when discussing risk with people whose 10-year score is below 10%.
- Recruit GPs through professional networks, with university ethics approval in place.
- Conduct semi-structured interviews and analyse them with reflexive thematic analysis.
- Compare interview themes with the wording of the NG238 recommendation.
Data Sources and Ethics Routes for Cardiology Projects
Matching your topic to the right data source is half the project. The table summarises what each source offers and what access involves, based on each provider’s published information at the time of writing. Check each provider’s current terms before you rely on them.
| Source | What it offers | Access note |
|---|---|---|
| NICOR National Cardiac Audit Programme | Six domains covering adult cardiac surgery, congenital heart disease, cardiac rhythm management, MINAP, heart failure and percutaneous coronary intervention, plus a TAVI registry | Published reports and interactive TAVI reports are open; patient-level data needs a formal application |
| CVDPREVENT | GP record audit of atrial fibrillation, hypertension, high cholesterol, diabetes, non-diabetic hyperglycaemia and chronic kidney disease | Open aggregate data; no patient access needed |
| NHSBSA English Prescribing Dataset with SNOMED codes | Monthly dispensed prescription items in England | Open data; shows drugs dispensed, not diagnoses |
| BHF statistics compendium | UK heart and circulatory disease mortality, morbidity and more | Free to download |
| UK Biobank | Large cohort with questionnaire, biological and imaging data, including cardiac MRI | Application through its access system; a reduced student fee exists for data-only requests, so check current terms |
| Our Future Health | More than two million consented participants; questionnaire, clinic measures, genotype array and linked NHS England records | Access board approval; analysis in a secure environment with quarterly releases |
| CPRD | UK primary care records with linkage to hospital and death data | Protocol review by an independent scientific committee; usually through a university licence |
| GBD Results Tool | Global estimates of cardiovascular burden by country | Free for non-commercial use; registration may be needed |
| NHANES | United States survey with blood pressure and other cardiovascular measures | Public-use files available to download |
Ethics rules depend on your level. The Health Research Authority no longer accepts standalone undergraduate research for NHS research ethics committee review or HRA approval, and some Master’s projects are also ineligible. Its student research toolkit shows which route applies to you. Even when NHS ethics is not required, you may still need university ethics approval and NHS research and development permission. Read the guide to ethics approval for a dissertation and ask your supervisor early. Rules also differ by country, so check your own university’s requirements.
Choosing a Cardiology Topic by Level: Undergraduate, Master’s and PhD
At undergraduate level, choose questions you can answer with published studies, open reports or open data: systematic reviews, guideline comparisons and audit-report analysis. These topics avoid NHS ethics barriers and fit a single academic year.
At Master’s level, add original analysis. That could be an interrupted time series on prescribing data, a diagnostic accuracy meta-analysis, a health economic model or interviews with health professionals recruited for their role. The how to choose research topics guide and the dissertation topic finder can help you narrow a shortlist.
At PhD level, look for questions that need new data, linked records or novel methods, such as polygenic risk modelling, biobank analyses or evaluation of AI tools. Supervisors and funders matter as much as the idea, so read advertised PhD projects to see what groups are actually funding.
Common Mistakes in Cardiology Dissertations
- Mixing ejection fraction categories without defining them. Choose one guideline’s definitions and use them throughout.
- Treating prescribing counts as treatment of a diagnosis. Dispensing data do not record why a drug was prescribed.
- Assuming NHS access at undergraduate level. Check the HRA rules before you promise anything to your supervisor.
- Citing outdated guidance. Several guidelines named above were updated recently or are being updated, so date every recommendation.
- Ignoring confounding and selection. UK Biobank volunteers are healthier than the general population, and hospital cohorts differ from community ones.
- Forgetting measurement variability. If your study uses echocardiography, use one trained operator or report inter-observer agreement.
- Promising long follow-up in a short project. Choose outcomes you can observe within your timeline, and plan with the dissertation timeline planner.
Cardiology Dissertation FAQs
Can I use NHS patient data for an undergraduate cardiology dissertation?
Usually not. The HRA does not permit NHS research ethics review of standalone undergraduate projects, so most undergraduates use published studies, open data or audit reports instead. Your university’s own rules apply, so confirm them with your supervisor.
Which topics here need no NHS ethics approval?
Topics based on published literature, guideline documents, open datasets such as CVDPREVENT, the NHSBSA prescribing data, GBD and NHANES files, and systematic or scoping reviews. You still need to confirm requirements with your university.
What is the difference between a service evaluation and research in cardiology?
The HRA’s decision tool helps you check whether an activity counts as research. A local audit of whether care follows a standard is usually service evaluation, while work designed to produce generalisable knowledge is research. Never decide this alone: ask the trust and your supervisor first.
Is a systematic review enough for a Master’s dissertation?
Yes, if the question is focused, the protocol is clear and the analysis goes beyond description. Register or document your protocol before screening, and where studies are similar enough, add a meta-analysis. The primary and secondary research guide explains where reviews fit.
Turning a Topic Into a Research Plan
Once you have a shortlist, convert each idea into a research question with the research question generator, and check the sample size or analysis plan with the statistical test selector. The guides on aims, objectives and research questions and choosing a research methodology explain how to justify each decision.
Need help narrowing a topic into a proposal? Research proposal writing support and medical dissertation help offer guidance on structure, methods and referencing. All topics here are free to use, and any model or reference work should be adapted in line with your institution’s academic integrity policy.